Oncology Institute Shares Climb on Raised FY25 Outlook

Dow Jones11-14

By Elias Schisgall

Shares of the Oncology Institute rose after the company raised its outlook following a quarter of revenue growth.

The stock was up 15% in after-hours trading, at $3.57. Ahead of Thursday's close, the stock had risen nearly tenfold year-to-date.

The company, which focuses on cancer care, posted a third-quarter loss of $16.5 million, or 14 cents a share, compared with a loss of $16.1 million, or 18 events a share, a year earlier.

Analysts polled by FactSet were expecting a loss of 11 cents a share.

Operating revenue rose to $136.6 million, compared with $99.9 million a year earlier. The increase was fueled by a rise in dispensary and patient services revenue, while partially offset by a dip in revenue from clinical trials.

The company upped its full-year guidance to between $495 million and $505 million, from prior guidance of between $460 million and $480 million. Analysts polled by FactSet were expecting $474.1 million.

Chief Executive Daniel Virnich said Oncology Institute was able to raise its outlook based on growth in its pharmacy business and a strong performance in Florida, as well as its implementation of artificial intelilgence in operations and the patient experience.

"As a leader in oncology value-based care, it is important for us to not only raise the quality of care but also lower that cost of care," Virnich said. "We believe we are well-positioned to achieve this goal, while simultaneously driving durable and sustainable growth."

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

November 13, 2025 18:03 ET (23:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583543828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 07:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583543828","market":"hk","top_or_hot":-1,"title":"Oncology Institute Shares Climb on Raised FY25 Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of the Oncology Institute rose after the company raised its outlook following a quarter of revenue growth. \n</p>\n<p>\n  The stock was up 15% in after-hours trading, at $3.57. Ahead of Thursday's close, the stock had risen nearly tenfold year-to-date. \n</p>\n<p>\n  The company, which focuses on cancer care, posted a third-quarter loss of $16.5 million, or 14 cents a share, compared with a loss of $16.1 million, or 18 events a share, a year earlier. \n</p>\n<p>\n  Analysts polled by FactSet were expecting a loss of 11 cents a share. \n</p>\n<p>\n  Operating revenue rose to $136.6 million, compared with $99.9 million a year earlier. The increase was fueled by a rise in dispensary and patient services revenue, while partially offset by a dip in revenue from clinical trials. \n</p>\n<p>\n  The company upped its full-year guidance to between $495 million and $505 million, from prior guidance of between $460 million and $480 million. Analysts polled by FactSet were expecting $474.1 million. \n</p>\n<p>\n  Chief Executive Daniel Virnich said Oncology Institute was able to raise its outlook based on growth in its pharmacy business and a strong performance in Florida, as well as its implementation of artificial intelilgence in operations and the patient experience. \n</p>\n<p>\n  \"As a leader in oncology value-based care, it is important for us to not only raise the quality of care but also lower that cost of care,\" Virnich said. \"We believe we are well-positioned to achieve this goal, while simultaneously driving durable and sustainable growth.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2025 18:03 ET (23:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncology Institute Shares Climb on Raised FY25 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncology Institute Shares Climb on Raised FY25 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-14 07:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of the Oncology Institute rose after the company raised its outlook following a quarter of revenue growth. \n</p>\n<p>\n  The stock was up 15% in after-hours trading, at $3.57. Ahead of Thursday's close, the stock had risen nearly tenfold year-to-date. \n</p>\n<p>\n  The company, which focuses on cancer care, posted a third-quarter loss of $16.5 million, or 14 cents a share, compared with a loss of $16.1 million, or 18 events a share, a year earlier. \n</p>\n<p>\n  Analysts polled by FactSet were expecting a loss of 11 cents a share. \n</p>\n<p>\n  Operating revenue rose to $136.6 million, compared with $99.9 million a year earlier. The increase was fueled by a rise in dispensary and patient services revenue, while partially offset by a dip in revenue from clinical trials. \n</p>\n<p>\n  The company upped its full-year guidance to between $495 million and $505 million, from prior guidance of between $460 million and $480 million. Analysts polled by FactSet were expecting $474.1 million. \n</p>\n<p>\n  Chief Executive Daniel Virnich said Oncology Institute was able to raise its outlook based on growth in its pharmacy business and a strong performance in Florida, as well as its implementation of artificial intelilgence in operations and the patient experience. \n</p>\n<p>\n  \"As a leader in oncology value-based care, it is important for us to not only raise the quality of care but also lower that cost of care,\" Virnich said. \"We believe we are well-positioned to achieve this goal, while simultaneously driving durable and sustainable growth.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2025 18:03 ET (23:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TOI","symbol_name":"The Oncology Institute","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2583543828","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583543828","pubTimestamp":1763074980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of the Oncology Institute rose after the company raised its outlook following a quarter of revenue growth.The stock was up 15% in after-hours trading, at $3.57. Ahead of Thursday's close, the stock had risen nearly tenfold year-to-date.The company, which focuses on cancer care, posted a third-quarter loss of $16.5 million, or 14 cents a share, compared with a loss of $16.1 million, or 18 events a share, a year earlier.Operating revenue rose to $136.6 million, compared with $99.9 million a year earlier. The increase was fueled by a rise in dispensary and patient services revenue, while partially offset by a dip in revenue from clinical trials.Chief Executive Daniel Virnich said Oncology Institute was able to raise its outlook based on growth in its pharmacy business and a strong performance in Florida, as well as its implementation of artificial intelilgence in operations and the patient experience.\"As a leader in oncology value-based care, it is important for us to not only rais","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TOI":"The Oncology Institute","BK4185":"保健护理机构"},"translate_title":"肿瘤研究所股价因2025财年前景上调而攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOI":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of the Oncology Institute rose after the company raised its outlook following a quarter of revenue growth. \n\n\n  The stock was up 15% in after-hours trading, at $3.57. Ahead of Thursday's close, the stock had risen nearly tenfold year-to-date. \n\n\n  The company, which focuses on cancer care, posted a third-quarter loss of $16.5 million, or 14 cents a share, compared with a loss of $16.1 million, or 18 events a share, a year earlier. \n\n\n  Analysts polled by FactSet were expecting a loss of 11 cents a share. \n\n\n  Operating revenue rose to $136.6 million, compared with $99.9 million a year earlier. The increase was fueled by a rise in dispensary and patient services revenue, while partially offset by a dip in revenue from clinical trials. \n\n\n  The company upped its full-year guidance to between $495 million and $505 million, from prior guidance of between $460 million and $480 million. Analysts polled by FactSet were expecting $474.1 million. \n\n\n  Chief Executive Daniel Virnich said Oncology Institute was able to raise its outlook based on growth in its pharmacy business and a strong performance in Florida, as well as its implementation of artificial intelilgence in operations and the patient experience. \n\n\n  \"As a leader in oncology value-based care, it is important for us to not only raise the quality of care but also lower that cost of care,\" Virnich said. \"We believe we are well-positioned to achieve this goal, while simultaneously driving durable and sustainable growth.\" \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 18:03 ET (23:03 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583543828","isCrawlerRequest":true}